AstraZeneca stock gains after Goldman Sachs lifts price target

Published on 09/18/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock trades further below its 52-week high after a recent London close of 122.85 GBP on September 17, 2026. Goldman Sachs raised its price target to 16,526 pence on September 18, 2026, keeping a Buy rating.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock (ISIN GB0009895292) recently closed at 122.85 GBP on the London Stock Exchange on September 17, 2026, leaving the shares 21.9% below a 52-week high of 157.30 GBP and above a 52-week low of 107.84 GBP.

Goldman Sachs raises AstraZeneca target

As dpa-AFX reported on September 18, 2026, Goldman Sachs raised its price target for AstraZeneca from 16,300 pence to 16,526 pence while maintaining a Buy rating.

According to Morningstar Alliance News on September 18, 2026, this new target of 16,526 pence represents a modest uplift from the previous 16,300 pence, signaling incremental confidence in AstraZeneca's medium term earnings potential.

Stock trades in the middle of its 52-week range

Per a price overview dated September 17, 2026, AstraZeneca shares closed at 122.85 GBP in London, up 1.2% versus the prior day, while remaining 21.9% below the 52-week high of 157.30 GBP and above the 52-week low of 107.84 GBP, placing the stock in the middle of its yearly trading band.

According to a London market wrap cited in the same context on September 17, 2026, the 52-week high of 157.30 GBP was reached on February 19, 2026, while the 52-week low of 107.84 GBP dates back to September 27, 2025, illustrating that the current level leaves investors with upside potential of 27.9% back to the high if that peak were revisited.

US listing shows different absolute levels but similar range

On the US listing, AstraZeneca PLC American depositary shares most recently closed at 162.89 USD on the New York Stock Exchange as of September 18, 2026, with a subsequent intraday quote around 166.13 USD indicating a gain of 1.99% or 3.24 USD from the prior close.

According to a US stock portal snapshot dated September 18, 2026, the US line of AstraZeneca traded over the past 52 weeks between a low of 145.79 USD and a high of 212.71 USD, placing the current intraday level of 166.13 USD roughly one third of the way between those extremes and underscoring a similar mid range position as in London.

Clinical data underpin analyst optimism

As Yahoo Finance reported on September 18, 2026, AstraZeneca disclosed strong trial results for its lung drug candidate tozorakimab in chronic obstructive pulmonary disease, a development that analysts see as a major opportunity to expand the company’s respiratory franchise.

According to the same report from Yahoo Finance on September 18, 2026, the positive data for tozorakimab strengthen AstraZeneca’s late stage pipeline at a time when investors are closely watching the balance between patent expiries and new product launches.

Stock level and investor perspective

For investors, the combination of a London close at 122.85 GBP on September 17, 2026, a 52-week high of 157.30 GBP and a 52-week low of 107.84 GBP highlights that AstraZeneca stock is trading closer to the middle of its recent range while recent analyst target increases and favorable clinical data add support to the medium term narrative.